Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Liver Diseases

  Free Subscription

Articles published in Lancet

Retrieve available abstracts of 27 articles:
HTML format

Single Articles

    April 2024
  1. KARLSEN TH, Rutter H, Carrieri P, Zelber-Sagi S, et al
    The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
    Lancet. 2024;403:1522-1524.

    November 2023
  2. VON KODOLITSCH Y, Kubisch C, Carrel T
    AATD as a genetic risk factor for aneurysmal disease - Authors' reply.
    Lancet. 2023;402:1626.

    AATD as a genetic risk factor for aneurysmal disease.
    Lancet. 2023;402:1625-1626.

    October 2023
  4. VOGEL A, Meyer T, Saborowski A
    IMbrave050: the first step towards adjuvant therapy in hepatocellular carcinoma.
    Lancet. 2023 Oct 23:S0140-6736(23)01962-1. doi: 10.1016/S0140-6736(23)01962.

  5. QIN S, Chen M, Cheng AL, Kaseb AO, et al
    Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
    Lancet. 2023 Oct 20:S0140-6736(23)01796-8. doi: 10.1016/S0140-6736(23)01796.
    PubMed     Abstract available

    September 2023
  6. PINATO DJ, D'Alessio A, Celsa C, Manfredi GF, et al
    The price and value of therapeutic synergy in liver cancer.
    Lancet. 2023;402:1108-1110.

  7. TAPPER EB, Serper M
    Screening for advanced liver disease in the general population.
    Lancet. 2023;402:941-943.

  8. SERRA-BURRIEL M, Juanola A, Serra-Burriel F, Thiele M, et al
    Development, validation, and prognostic evaluation of a risk score for long-term liver-related outcomes in the general population: a multicohort study.
    Lancet. 2023;402:988-996.
    PubMed     Abstract available

    August 2023
  9. YAQUB S, Bjork I, Sugulle M, Folseraas T, et al
    Biopsy helpful in diagnosing a liver mass in pregnancy: focal nodular hyperplasia.
    Lancet. 2023;402:e10.

    July 2023
  10. QIN S, Chan SL, Gu S, Bai Y, et al
    Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study.
    Lancet. 2023 Jul 24:S0140-6736(23)00961-3. doi: 10.1016/S0140-6736(23)00961.
    PubMed     Abstract available

    May 2023
  11. ADAMS PC, Jeffrey G, Ryan J
    Lancet. 2023;401:1811-1821.
    PubMed     Abstract available

    April 2023
  12. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.

  13. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available

    February 2023
  14. ALLISON MED, Verne J, Bernal W, Clayton M, et al
    Deaths from alcohol-related liver disease in the UK: an escalating tragedy.
    Lancet. 2023;401:418-420.

    September 2022
  15. VOGEL A, Meyer T, Sapisochin G, Salem R, et al
    Hepatocellular carcinoma.
    Lancet. 2022 Sep 6. pii: S0140-6736(22)01200.
    PubMed     Abstract available

    January 2022
  16. COOKE GS, Nayagam S
    Liver disease: at the heart of public health challenges for Europe in the 21st century.
    Lancet. 2022;399:9-10.

  17. KLEINERT S, Horton R
    An urgent challenge for Europe: from tackling liver diseases to protecting liver health.
    Lancet. 2022;399:7-9.

    December 2021
  18. NHLANE R, Kreuels B, Mallewa J, Chetcuti K, et al
    Late presentation of hepatocellular carcinoma highlights the need for a public health programme to eliminate hepatitis B.
    Lancet. 2021;398:2288.

  19. WATTS G
    Tom Hemming Karlsen: hepatologist with a public health message.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)02746.

  20. KARLSEN TH, Sheron N, Zelber-Sagi S, Carrieri P, et al
    The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.
    Lancet. 2021 Dec 1. pii: S0140-6736(21)01701.

    October 2021
  21. GONZALES E, Hardikar W, Stormon M, Baker A, et al
    Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
    Lancet. 2021;398:1581-1592.
    PubMed     Abstract available

  22. KRIEGERMEIER A, Taylor S
    Apical sodium-dependent bile acid transporter inhibition in children with Alagille syndrome.
    Lancet. 2021;398:1544-1545.

    September 2021
  23. GINES P, Krag A, Abraldes JG, Sola E, et al
    Liver cirrhosis.
    Lancet. 2021 Sep 17. pii: S0140-6736(21)01374.
    PubMed     Abstract available

  24. GURNARI C, Colak C, Zawit M, Maciejewski JP, et al
    Chronic Budd-Chiari syndrome in paroxysmal nocturnal haemoglobinuria.
    Lancet. 2021;398:e14.

    August 2021
  25. TIAN M, Zhang Z, Yuan Y
    When a young hepatobiliary surgeon faces his own liver lesions diagnosis.
    Lancet. 2021;398:746.

    April 2021
  26. POWELL EE, Wong VW, Rinella M
    Non-alcoholic fatty liver disease.
    Lancet. 2021 Apr 21. pii: S0140-6736(20)32511.
    PubMed     Abstract available

    March 2021
  27. WILLIAMS R, Alessi C, Alexander G, Allison M, et al
    New dimensions for hospital services and early detection of disease: a Review from the Lancet Commission into liver disease in the UK.
    Lancet. 2021 Mar 10. pii: S0140-6736(20)32396.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.